Assessment of the role of the Xpert Bladder Cancer detect assay in patients with asymptomatic hematuria
- Conditions
- R31D41.4C67Unspecified haematuriaBladderMalignant neoplasm of bladder
- Registration Number
- DRKS00027469
- Lead Sponsor
- Cepheid Europe SAS
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete
- Sex
- All
- Target Recruitment
- 400
Inclusion Criteria
hematuria
Exclusion Criteria
known bladder tumor
Study & Design
- Study Type
- observational
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Exclusion / evidence of a bladder tumor
- Secondary Outcome Measures
Name Time Method Predictive value of tumor markers
Related Research Topics
Explore scientific publications, clinical data analysis, treatment approaches, and expert-compiled information related to the mechanisms and outcomes of this trial. Click any topic for comprehensive research insights.
What molecular biomarkers does the Xpert Bladder Cancer detect assay target in urothelial carcinoma diagnosis?
How does the Xpert Bladder Cancer detect assay compare to cystoscopy in detecting C67.9 malignant bladder tumors in asymptomatic hematuria patients?
Which urinary biomarkers correlate with Xpert assay performance in R31 unspecified hematuria cases with bladder cancer risk?
What adverse events are associated with Xpert Bladder Cancer detect assay-guided diagnostic workflows in D41.4 bladder neoplasm screening?
How does Cepheid's Xpert Bladder Cancer detect assay integrate with FGFR3/TP53 mutation testing for bladder cancer subtyping?